Drug Orforglipron and Diabetes-Obesity Care
Summary of News
Orforglipron is a new type of GLP-1 medicine being tested for diabetes and weight loss. GLP-1 medicines help the body control blood sugar and reduce appetite. Existing popular GLP-1 drugs often come as injections and may need careful storage or usage rules. The importance of Orforglipron is that it is a pill. It does not need cold-chain storage like some injectable medicines, and it does not require very strict food-water timing. This can make it easier to use, store, transport, and distribute, especially in countries with large populations and weaker health infrastructure. Core idea: Orforglipron matters because it can make advanced diabetes and weight-loss treatment more accessible, convenient, and scalable.
Static Link (Preview)
Incretins, GLP-1 receptor agonists, non-communicable diseases, India’s diabetes burden.
UPSC Trap (Preview)
Treating GLP-1 drugs as only “weight-loss drugs” and ignoring diabetes/NCD burden.
Possible MCQ Question
Q.With reference to GLP-1 receptor agonists, consider the following statements.
- A.1. GLP-1 receptor agonists can enhance glucose-dependent insulin secretion and reduce appetite.
- B.2. Orforglipron is an oral non-peptide small molecule and does not require cold-chain like peptide injectables.
- C.3. HbA1c reflects average blood glucose only for the previous 24 hours.
- D.Select correct answer code :
- E.A. 1 and 2 only
- F.B. 2 and 3 only
- G.C. 1 and 3 only
- H.D. 1, 2 and 3
Unlock the Full Decoder
Full decoder, answer, explanation and elimination clue are available inside the Prelims Antishock Tool.
- • Revision of static
- • Second-layer / hidden angles
- • Evidence-to-process reasoning
- • MCQ answer + explanation
- • Elimination clue line
- • Final Antishock takeaway